Ritanserin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ritanserin
Ritanserin2DCSD.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard 100.163.772
Chemical and physical data
Molar mass 477.569 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research.[1]

Research[edit]

Ritanserin was tested in clinical trials for schizophrenia[2] and migraine.[3]

Pharmacology[edit]

Ritanserin acts as a selective 5-HT2A (Ki = 0.45 nM) and 5-HT2C receptor (Ki = 0.71 nM) antagonist.[2][4] It has relatively low affinity for the H1, D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively).[4] The affinity of ritanserin for the 5-HT1A receptor is than 1 µM.[4] In addition to its affinity for the 5-HT2A and 5-HT2C receptors, ritanserin also binds to and antagonizes the 5-HT1D, 5-HT2B, 5-HT5A, 5-HT6, and 5-HT7 receptors.[5]

The atypical antipsychotic risperidone was developed from ritanserin.[6]

See also[edit]

References[edit]

  1. ^ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 249–. ISBN 978-0-7514-0499-9. 
  2. ^ a b Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA (September 2008). "Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study". Progress in neuro-psychopharmacology & biological psychiatry. 32 (8): 1879–83. PMID 18801405. doi:10.1016/j.pnpbp.2008.08.020. 
  3. ^ Nappi, G; Sandrini, G; Granella, F; Ruiz, L; Cerutti, G; Facchinetti, F; Blandini, F; Manzoni, GC (June 1990). "A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline.". Headache. 30 (7): 439–44. PMID 2119355. doi:10.1111/j.1526-4610.1990.hed3007439.x. 
  4. ^ a b c Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985). "Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.". Mol Pharmacol. 27 (6): 600–11. PMID 2860558. 
  5. ^ Harmful Non-Indigenous Species in the United States. DIANE Publishing. 1 February 1993. pp. 361–. ISBN 978-0-7881-0441-1. 
  6. ^ Bentham Science Publishers (May 1994). Current Medicinal Chemistry. Bentham Science Publishers. pp. 52–.